Erratum: The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart (Mol Cell Biochem, (2013) 381,1-2, (301-311), 10.1007/s11010-013-1712-9);The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart

Molecular and Cellular Biochemistry

Volumn 381, Issue 1-2, 2013, Pages 301-311

  Barudzic, Nevena ^a   Turjacanin Pantelic, Drenka ^b   Zivkovic, Vladimir ^a   Selakovic, Dragica ^a   Srejovic, Ivan ^a   Jakovljevic, Jovana ^a   Djuric, Dragan M ^b   Jakovljevic, Vladimir Lj ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cardiac function; COX inhibitors; Isolated rat heart; Oxidative stress

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ARGININE; HYDROGEN PEROXIDE; MELOXICAM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN OXIDE; OXYGEN; PROSTAGLANDIN SYNTHASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME INHIBITION; HEART; HEART FUNCTION; HEART PERFUSION; IN VITRO STUDY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERFUSION PRESSURE; RAT;

RATTUS;

EID: 84882611295     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1742-3     Document Type: Erratum

References (57)

1. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91(8):3228-3232. doi: 10.1073/pnas.91.8.3228
2. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M (2005) Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric oxide synthase and oxidative stress. J Pharmacol Exp Ther 312(3):945-953. doi:10.1124/jpet.104.077644
3. Oshima K, Takeyoshi I, Tsutsumi H, Mohara J, Ohki S, Koike N, Nameki T, Matsumoto K, Morishita Y (2006) Inhibition of cyclooxygenase-2 improves cardiac function following long-term preservation. J Surg Res 135(2):380-384. doi: 10.1016/j.jss.2006.03.044
4. Fu Y, Wang Z, Chen WL, Moore PK, Zhu YZ (2007) Cardio-protective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol 293(3):H1545-H1552. doi:10.1152/ajpheart.00064.2007
5. Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528. doi:10.1056/ NEJM200011233432103
6. Gottlieb S (2001) COX-2 inhibitors may increase risk of heart attack. BMJ 323:471. doi:10.1136/bmj.323.7311.471/a
7. Cunnington M, Webb D, Qizilbash Net al(2008) Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf 17:601-608. doi: 10.1002/pds.1590
8. Sorensen R, Abildstrom SZ, Torp-Pedersen C, Gislason GH (2008) Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. J Cardiovasc Nurs 23:14-19. doi:10.1097/01
9. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A (2004) Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 37:71-77. doi:10.1016
10. Straino S, Salloum FN, Baldi A et al (2007) Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol 50:571-577. doi:10.1097/FJC.0b013e31814b91cb
11. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP (2004) Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286:H1416-H1424. doi:10.1152/ajpheart. 00136.2003
12. Timmers L, Sluijter JP, Verlaan CW et al (2007) Cyclooxygen-ase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 23:326-332. doi:10.1161/CIR CULATIONAHA.106.647230
13. Mason RP, Walter MF, Day CA, Jacob RF (2007) A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell Biochem 42:175-190
14. 2+ channels in neonatal rat ventricular cardiomyocytes. Korean Physiol Soc Korean Soc Pharmacol 13(6):437-442. doi: 10.4196/kjpp.2009.13.6.437
15. Seon MB, Jin SA, Hae SN, Jaeyong P, Sang SK, Deok RK (2010) Proteomic analysis in NSAIDs-treated primary cardiomyocytes. J Proteomics 73(4):721-732. doi:10.1016/j.jprot.2009.10.004
16. Weiss HA, Forman D (1996) Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. Scand J Gastroenterol 200(31):137-141
17. Villegas I, Martín MJ, La Casa C, Motilva V, De La Lastra CA (2002) Effects of oxicam inhibitors of cyclooxygenase on oxi-dative stress generation in rat gastric mucosa. A comparative study. Free Radic Res 36(7):769-77
18. Burak Cimen MY, Cimen OB, Eskandari G, Sahin G, Erdoǧan C, Atik U (2003) In vivo effects of meloxicam, celecoxib, and ibu-profen on free radical metabolism in human erythrocytes. Drug Chem Toxicol 26(3):169-176. doi:10.1081/DCT-120022645
19. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP (2004) Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177(2):235-243. doi::10.1016/j.atherosclerosis.2004.10.001
20. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
21. Novokmet S, Jakovljevic VLj, Jankovic S, et al. (2009) Human platelets perfusion through isolated guinea-pig heart: the effects on coronary flow and oxidative stress markers. Gen Physiol Biophys 28:98-104
22. Heindl B, Becker BF (2001) Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function. Naunyn Schmiedebergs Arch Pharmacol 363(2):233-240. doi:10.1007/s002100000349
23. Auclair C, Voisin E (1985) Nitroblue tetrazolium reduction. In: Greenvvald RA (ed) Handbook of methods for oxygen radical research. CRC Press, Boca Raton, pp 123-132
24. Pick E, Keisari Y (1980) A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 38:161-170. doi:10.1016/0022-1759(80)90340-3
25. Karmazyn M, Neely JR (1988) Evidence for a direct protective effect pf aspirin on the ischemic and reperfused heart. Circulation 78:16
26. Zivkovic V, Djuric D, Turjacanin-Pantelic D, Marinkovic Z, Stefanovic Dj, Srejovic I, Jakovljević VLj (2013) The effects of cyclooxygenase and nitric oxide synthase inhibition on cardio-dynamic parameters and coronary flow in isolated rat heart. Exp Clin Cardiol (in press)
27. Kawabata H, Sugiyama K, Katori R (1996) Effect of acetylsali-cylic acid on metabolism and contractility in the ischemic rep-erfused heart. Jpn Circ J 60:961-971. doi:10.1253/jcj.60.961
28. Djurić D, Vusanović A, Jakovljević VLj (2007) The effects of folic acid and nitric oxide synthase inhibition on coronary flow and oxidative stress markers in isolated rat heart. Mol Cell Bio-chem 300(1-2):177-183. doi:10.1007/s11010-006-9381-6
29. Radomski MW, Palmer RM, Moncada S (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87:5193-97
30. Kumar S, Prahalathan P, Raja B (2011) Antihypertensive and anti-oxidant potential of vanillic acid, a phenolic compound in L-NAME-induced hypertensive rats: a dose-dependence study. Redox Rep 16(5):208-215. doi:10.1179/1351000211Y. 0000000009
31. Kopff M, Kopff A, Kowalczyk E (2007) The effects of nonste-roidal anti-inflammatory drugs on oxidative/antioxidative balance. Pol Merkur Lekarski 23(135):184-7
32. Adderley SR, Fitzgerald DJ (1999) Oxidative damage of cardio-myocytes is limited by extracellular regulated kinases 1/2-medi-ated induction of cyclooxygenase-2. J Biol Chem 274:5038-5046. doi:10.1074/jbc.274.8.5038
33. Mahmood K-AS, Jawad HA, Jawad AM (2009) Non-steroidal anti-inflammatory drugs (NSAIDs), free radicals and reactive oxygen species (ros): a review of literature. MJBU 27. doi:10. 1517/14740338.2011.529898
34. Wu R, Lamontagne D, de Champlain J (2002) Antioxidative properties of acetylsalicylic Acid on vascular tissues from nor-motensive and spontaneously hypertensive rats. Circulation 105(3):387-392. doi:10.1161/hc0302.102609
35. Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655-673
36. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
37. Stoffels B, Yonezawa K, Yamamoto Y, Shaefer N, Overhaus M, Klinge U, Kalff JC, Minor T, Tolba RH (2011) Meloxicam, a COX-2 inhibitor, ameliorates ischemia/reperfusion injury in non-heart beating donor livers. Eur Sur Res 47:109-117. doi:10.1159/000329414
38. TakeyoshiI, SunoseY, IwazakiS, TsutsumiH, AibaM, Kasahara M, Ohwada S, Matsumoto K, Morishita Y (2001) The effect of a selective cyclooxygenase-2 inhibitorin extended liver resection with ischemiaindogs.JSurg Res 100:25-31. doi:10.1006/jsre.2001.6211
39. OshimaK, Yabata Y, YoshinariD, Takeyoshi I (2009) The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation. J Invest Surg 22:239-245, PIMD 19842898
40. Gupta YK, Chaudhary G, Sinha K (2002) Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat. Can J Physiol Pharmacol. 80(3):210-7
41. Chu LM, Robich MP, Bianchi C, Feng J, Liu Y, Xu SH, Burgess T, Sellke FW (2012) Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia. Am J Physiol Heart Circ Physiol 302(2):H479-H488. doi:10.1152/ajpheart.00146.2011
42. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105:575-80, PMC1908438
43. Fu Y, Wang Z, Chen WL, Moore PK, Zhu YZ (2007) Cardio-protective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol 293:H1545-H1552. doi:10.1152/ajpheart.00064.2007
44. Farkouh ME, Greenberg BP (2009) An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 103:1227-1237. doi:10.1016/j.amjcard.2009.01.014
45. Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo controlled trials: the cross trial safety analysis. Circulation 117:2104-2113. doi:10.1161/CIRCULATIONAHA.108.764530
46. Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470-479. doi: 10.1097/FJC.0b013e318157f72d
47. Sojitra B, Bulani Y, Putcha UK, Kanwal A, Gupta P, Kuncha M, Banerjee SK (2012) Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice. Mol Cell Biochem 360(1-2):61-69. doi:10.1007/s11010- 011-1044-6
48. Kwiecien S, Konturek PC, Sliwowski Z, Mitis-Musiol M, Pawlik MW, Brzozowski B, Jasnos K, Magierowski M, Konturek SJ, Brzozowski (2012) Interaction between selective cyclooxygenase inhibitors and capsaicin-sensitive afferent sensory nerves in pathogenesis of stress-induced gastric lesions. Role of oxidative stress. J Physiol Pharmacol. 63(2):143-51
49. Kwiecien S, Pawlik MW, Brzozowski T, Pawlik WW, Konturek SJ (2010) Reactive oxygen metabolite action in experimental, stress model of gastric mucosa damage. Gastroenterol Pol 17:234-243
50. Kwiecien S, Brzozowski T, Konturek SJ (2002) Effects of reactive oxygen species action on gastric mucosa in various models of mucosal injury. J Physiol Pharmacol 53:39-50
51. Kane MO, Etienne-Selloum N, Madeira SV, Sarr M, Walter A, Dal-Ros S, Schott C, Chataigneau T, Schini-Kerth VB (2010) Endothelium-derived contracting factors mediate the Ang II-induced endothelial dysfunction in the rat aorta: preventive effect of red wine polyphenols. Pflugers Arch 459(5):671-679. doi: 10.1007/s00424-009-0759-7
52. Félétou M, Huang Y, Vanhoutte PM (2011) Endothelium-medi-ated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164:894-912. doi:10.1111/j.1476-5381.2011.01276.x
53. Jakovljevic VLj, Kostic MM, Mujovic VM, Nedeljkovic TI, Eurić DM (1999) Interaction between L-arginine/NO system and cyclooxigenase metabolic product of arachidonic acid in coronary autoregulation. J Physiol Pharmacol 50:63-74
54. Harder DR, Campbell Wb, Roman RJ (1995) Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 32:79-92
55. Rees DD, Palmer RJ, Moncada S (1990) Nitric oxide in microcirculation. In: Moncada S, Higgs EA (eds) Nitric oxide from L-arginine: a bioregulatory system, Excerpta Medica, Amsterdam, pp 427-438
56. Kostić MM, Schrader J (1992) Role of nitric oxide in reactive hyperemia of the guinea pig heart. Circ Res 70:208-212. doi: 10.1161/01.RES.70.1.208
57. Kostic MM, Pertonijevic MR, Jakovljevic VLj (1996) Role of nitric oxide in the regulation of coronary circulation. Physiol Res 45:273-78